Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DDO | Q99489 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353485 | 0.75 | AOC3 (0.38) | AOC3BRD4NPC1RAB9ALOXL2 | |
| SCHEMBL27537895 | 0.75 | AOC3 (0.35) | AOC3BRD4NPC1RAB9ALOXL2 | |
| SCHEMBL27760742 | 0.70 | ALDH1A1 (0.40) | NPC1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL4405510 | 0.70 | SLC6A4 (0.41) | NPC1RAB9ACYP2A6KDM4EALDH1A1 | |
| SCHEMBL22345616 | 0.70 | PRCP (0.43) | KDM4EMAPTALDH1A1 | |
| SCHEMBL31072716 | 0.70 | PRCP (0.43) | KDM4EMAPTALDH1A1 | |
| SCHEMBL4899647 | 0.68 | AOC3 (0.34) | AOC3BRD4NPC1RAB9ALOXL2 | |
| SCHEMBL73543 | 0.68 | AOC3 (0.47) | AOC3BRD4NPC1RAB9ALOXL2 | |
| SCHEMBL18199941 | 0.67 | HTR2C (0.42) | ALDH1A1 | |
| SCHEMBL4108681 | 0.67 | FLT3 (0.40) | AOC3BRD4NPC1RAB9ALOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004082686-A2 | USE OF COMPOUNDS WITH COMBINED 5-HT1A AND SSRI ACTIVITIES TO TREAT SEXUAL DYSFUNCTION | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | US | claimed |
| WO-2004082686-A2 | USE OF COMPOUNDS WITH COMBINED 5-HT1A AND SSRI ACTIVITIES TO TREAT SEXUAL DYSFUNCTION | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | US | disclosed |
| EP-1171434-A1 | TETRAHYDROISOQUINOLINYL-INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000064886-A1 | TETRAHYDROISOQUINOLINYL-INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | HTR5A, HTR1A, HTR3A | AOC3 358/4885BRD4 4421/4885NPC1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.